Related Experiment Video
Updated: May 23, 2026

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae
Published on: February 17, 2023
Diabetic cardiomyopathy and diastolic heart failure -- difficulties with relaxation
1Department of Internal Medicine and Cardiology, Krankenhaus Sachsenhausen, Teaching Hospital, Goethe University, Frankfurt, Germany. Teupe@em.uni-frankfurt.de
Insights
Diabetic cardiomyopathy significantly increases heart failure risk. Early diagnosis and treatment, including blood glucose control and specific heart failure medications, are crucial for better outcomes in diabetic patients.
Area of Science:
- Cardiology
- Endocrinology
- Diabetology
Background:
- Diabetic patients have a 4-5 times higher risk of heart failure.
- Hyperglycemia is key in diabetic cardiomyopathy development.
- Diabetic cardiomyopathy causes cardiac hypertrophy and stiffness, initially presenting as diastolic heart failure.
Purpose of the Study:
- To review the characteristics of diabetic cardiomyopathy.
- To discuss diagnostic methods for diastolic dysfunction.
- To outline current and potential therapeutic strategies.
Main Methods:
- Literature review of diabetic cardiomyopathy.
- Echocardiography and BNP measurement for diagnosis.
- Analysis of antidiabetic and heart failure medication effects.
Main Results:
- Diabetic cardiomyopathy progresses from diastolic to systolic heart failure.
- Echocardiography and BNP are effective diagnostic tools.
- Metformin is safe; incretin-based therapies may offer benefits.
Conclusions:
- Early detection and management of diabetic cardiomyopathy are vital.
- Optimal blood glucose and blood pressure control are essential.
- Specific heart failure therapies like ACE inhibitors are recommended.
Abstract:
Diabetic patients carry a four- to five-fold increased risk of heart failure. Hyperglycaemia plays a central role in the pathogenesis of diabetic cardiomyopathy. Diabetic cardiomyopathy represents a distinct structural and functional disorder of the myocardium characterized by cardiac hypertrophy and an increased myocardial stiffness. At an early stage, diabetic cardiomyopathy is manifested by diastolic heart failure with preserved ejection fraction. In some patients, diastolic dysfunction may progress to heart failure with reduced ejection fraction and result in overt systolic heart failure. Diastolic dysfunction can accurately be diagnosed by echocardiography and BNP measurement in daily clinical practice. Early treatment is prognostically important. Optimal control of blood glucose levels and blood pressure is beneficial. So far metformin is the only antidiabetic agent not associated with harm in diabetic patients with heart failure. Incretin-based therapies potentially provide cardiovascular benefits. ACE inhibitors, angiotensin-1 receptor antagonists and beta-blockers should be preferred in heart failure therapy.
More Related Videos
11:00Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
11:04Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism
Published on: September 1, 2014
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Cardiomyopathy IV: Restrictive Cardiomyopathy
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy V: Interprofessional Care